CLINICAL-LABORATORY DIAGNOSIS AND PROGNOSTIC SIGNIFICANCE OF DYSLIPIDEMIA AND INFLAMMATION MEDIATORS IN METABOLIC PHENOTYPES OF OSTEOARTHRITIS: A META-ANALYTIC SYNTHESIS
Keywords:
osteoarthritis, metabolic phenotypes, dyslipidemia, inflammatory mediators, meta-analysis, pooled odds ratios, mediation analysis, prognostic biomarkers, lipidomics, cytokine dysregulationAbstract
Osteoarthritis (OA) is a paradigmatic degenerative joint disease, with metabolic phenotypes characterized by dyslipidemia—manifested as hypertriglyceridemia, accumulation of oxidized low-density lipoprotein (oxLDL), and reduced high-density lipoprotein (HDL)—interacting with inflammatory mediators (interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α], C-reactive protein [CRP]). These interactions contribute to chondrocyte senescence, synovial effusion, and osteophyte formation via lipotoxic and inflammasome-mediated pathways.
This synthesis underscores the growing burden of metabolic OA (projected 1 billion cases by 2050) and metabolic comorbidities (MetS prevalence 40–60%), advocating for lipid-modulating and anti-inflammatory interventions. Future metabolomic studies are warranted to refine causal inference and inform biomarker-guided therapeutic strategies.
References
1. Baudart, P., Louati, K., Sellam, J., & Berenbaum, F. (2017). Association between osteoarthritis and dyslipidaemia: A systematic literature review and meta-analysis. RMD Open, 3(2), Article e000442. https://doi.org/10.1136/rmdopen-2017-000442
2. Xiong, J., Wu, Q., Zhang, L., Li, J., Li, Y., Liu, Y., Li, D., Liu, J., Luo, Z., & Zhang, Z. (2020). Dyslipidemia might be associated with an increased risk of osteoarthritis. Frontiers in Endocrinology, 11, Article 132. https://doi.org/10.3389/fendo.2020.00132
3. Yan, L., Ge, H., Xu, Q., Jin, D., Song, A., Yang, M., Cao, Y., & Zheng, Y. (2024). Dyslipidemia induced inflammation mediated the association between obesity and osteoarthritis: A population-based study. BMC Public Health, 24, Article 3105. https://doi.org/10.1186/s12889-024-20616-4
4. Mocanu, V., Timofte, D. V., Zără-Dănceanu, C.-M., & Labusca, L. (2024). Obesity, metabolic syndrome, and osteoarthritis require integrative understanding and management. Biomedicines, 12(6), Article 1262. https://doi.org/10.3390/biomedicines12061262
5. Herrero-Manley, L., Alabajos-Cea, A., Suso-Martí, L., Cuenca-Martínez, F., Calatayud, J., Casaña, J., Viosca-Herrero, E., Vázquez-Arce, I., Ferrer-Sargues, F. J., & Blanco-Díaz, M. (2023). Serum lipid biomarkers and inflammatory cytokines associated with onset and clinical status of patients with early knee osteoarthritis. Frontiers in Nutrition, 10, Article 1126796. https://doi.org/10.3389/fnut.2023.1126796
6. Lambova, S. N. (2023). Knee osteoarthritis—How close are we to disease-modifying treatment: Emphasis on metabolic type knee osteoarthritis. Life, 13(1), Article 140. https://doi.org/10.3390/life13010140
7. Castrogiovanni, P., Trovato, F. M., Ravalli, S., Di Rosa, M., Leonardi, A., Castorina, S., & Musumeci, G. (2021). Heterogeneity of lipid and protein cartilage profiles associated with metabolic osteoarthritis and type 2 diabetes. Journal of Proteome Research, 20(6), 3069–3082. https://doi.org/10.1021/acs.jproteome.1c00186
8. Lynskey, S. J., & Mobasheri, A. (2023). Biomarkers of osteoarthritis—A narrative review on causal links with metabolic syndrome. Journal of Clinical Medicine, 12(6), Article 2125. https://doi.org/10.3390/jcm12062125
9. Mobasheri, A., Bay-Jensen, A. C., & Kraus, V. B. (2023). Biomarkers for osteoarthritis: Current status and future prospects. Best Practice & Research Clinical Rheumatology, 37(2), Article 101852. https://doi.org/10.1016/j.berh.2023.101852
10. Wei, G., Lu, K., Huang, Y., Li, H., Li, Y., Zhang, X., Li, X., Zhang, Y., Li, Y., Wang, Y., & Li, Y. (2023). Risk of metabolic abnormalities in osteoarthritis: A new perspective to understand its pathological mechanisms. Bone Research, 11, Article 59. https://doi.org/10.1038/s41413-023-00301-9
